N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy
- Citation:
- Clin Breast Cancer vol 16 (1) 23-30
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- This research was also supported in part by funds from Bristol-Myers Squibb and Imclone systems.
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 5
- Parents:
- 734
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, CA-37404, 1U10CA180799, U10 CA060276, U10 CA037404, U10 CA180821, U10 CA063848, CA-25224, CA-60276, 1U10CA180790, U10 CA180790, P30 CA015083, CA-63848, U10 CA180882, U10CA180821, U10 CA180799, U10 CA180867, U10 CA025224
- Corr. Author:
- Authors:
- Jennifer A. Crozier Pooja P. Advani Betsy LaPlant Timothy Hobday Anthony J. Jaslowski Alvaro Moreno-Aspitia Edith A. Perez
- Networks:
- FL003, LAPS-MN026, PR028, WINCORP
- Study
- NCCTG-N0436
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- breast cancer, metastatic, EGFR, cetuximab, irinotecan